Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Asma Bourafai-Aziez, Mohammed Benabderrahmane, Hippolyte Paysant, Louis-Bastien Weiswald, Laurent Poulain, Ludovic Carlier, Delphine Ravault, Marie Jouanne, Gaël Coadou, Hassan Oulyadi, Anne-Sophie Voisin-Chiret, Jana Sopková-de Oliveira Santos & Muriel Sebban. (2021) Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1. Drug Design, Development and Therapy 15, pages 5035-5059.
Read now
Read now
Rahul Dhanda, Della Varghese, Vijay R Nadipelli, Maurizio Fava, Namita Joshi, Caitlyn T Solem, James A Graham, Susan M Learned & Christian Heidbreder. (2019) Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study. Patient Preference and Adherence 13, pages 1037-1050.
Read now
Read now
Ranjeet Prasad Dash, Nuggehally R. Srinivas & R. Jayachandra Babu. (2019) Use of sorbitol as pharmaceutical excipient in the present day formulations – issues and challenges for drug absorption and bioavailability. Drug Development and Industrial Pharmacy 45:9, pages 1421-1429.
Read now
Read now
Andrew N. Coogan, Maria M. Papachatzaki, Corinne Clemens, Alison Baird, Rossen M. Donev, Jozef Joosten, Venetia Zachariou & Johannes Thome. (2011) Haloperidol alters circadian clock gene product expression in the mouse brain. The World Journal of Biological Psychiatry 12:8, pages 638-644.
Read now
Read now
Articles from other publishers (50)
Tao Lv, Liping Wu, Longlong Li, Min Zhang, Qingyu Tan & Ping Liu. (2023) Oculogyric crisis symptoms related to risperidone treatment: a case report. BMC Psychiatry 23:1.
Crossref
Crossref
Catarina Moura & Nuno Vale. (2023) The Role of Dopamine in Repurposing Drugs for Oncology. Biomedicines 11:7, pages 1917.
Crossref
Crossref
Thian-Sze Wong, Guangzhi Li, Shiliang Li, Wei Gao, Geng Chen, Shiyi Gan, Manzhan Zhang, Honglin Li, Song Wu & Yang Du. (2023) G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Ali Mir, Montaha Almudhry, Shahid Bashir & Hamoud Khallaf. (2023) Oculogyric crisis induced by risperidone in a child with variant. Brain Disorders 9, pages 100070.
Crossref
Crossref
Nimra Mumtaz & Muhammad Omair Hassan. 2023. Cognizance of Schizophrenia:: A Profound Insight into the Psyche. Cognizance of Schizophrenia:: A Profound Insight into the Psyche
127
147
.
Anton Bespalov, Marcel van Gaalen & Thomas Steckler. 2023. Drug Development in Psychiatry. Drug Development in Psychiatry
207
224
.
Parina Asgharian, Cristina Quispe, Jesús Herrera-Bravo, Mahsa Sabernavaei, Kamran Hosseini, Haleh Forouhandeh, Tahereh Ebrahimi, Paria Sharafi-Badr, Vahideh Tarhriz, Saiedeh Razi Soofiyani, Paweł Helon, Jovana Rajkovic, Sevgi Durna Daştan, Anca Oana Docea, Javad Sharifi-Rad, Daniela Calina, Wojciech Koch & William C. Cho. (2022) Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update. Frontiers in Pharmacology 13.
Crossref
Crossref
Yoshihiro Iwamura, Tatsuo Nakayama, Atsushi Matsumoto, Yuji Ogi, Masataka Yamaguchi, Atsushi Kobayashi, Kenji Matsumoto, Yasunori Katsura, Naho Konoike, Katsuki Nakamura & Kazuhito Ikeda. (2022) Effect of dopamine receptor-related compounds on naïve common marmosets for auditory steady-state response. Journal of Neurophysiology 128:1, pages 229-238.
Crossref
Crossref
Hannah W. Haddad, Elena Boardman, Brooke Williams, Rama Mouhaffel, Adam M. Kaye & Alan D. Kaye. (2022) Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review. Health Psychology Research 10:2.
Crossref
Crossref
Gerd Laux. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
14
.
Gerd Laux. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1769
1782
.
Nikolaos Vlachos, Marios Lampros, Spyridon Voulgaris & George A. Alexiou. (2021) Repurposing Antipsychotics for Cancer Treatment. Biomedicines 9:12, pages 1785.
Crossref
Crossref
Habibur Rahman, S.K. Manirul Haque & Masoom Raza Siddiqui. (2020) A Comprehensive Review on Importance and Quantitation of Atypical Antipsychotic Drugs and their Active Metabolites in Commercial Dosage Forms. Current Pharmaceutical Analysis 16:8, pages 989-1019.
Crossref
Crossref
Guillermo Fernandez, Sabu Kuruvilla, Catherine D. G. Hines, Frédéric Poignant, James Marr, Thomas Forest & Richard Briscoe. (2019) Brain findings associated with risperidone in rhesus monkeys: magnetic resonance imaging and pathology perspectives. Journal of Toxicologic Pathology 32:4, pages 233-243.
Crossref
Crossref
Wei Zhou, Wushao Chang, Yucai Yan, Lu Shen, Wenqiang Li, Zhenghui Yi & Shengying Qin. (2018) Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients. Neuroscience Letters 683, pages 202-206.
Crossref
Crossref
Piotr Stępnicki, Magda Kondej & Agnieszka A. Kaczor. (2018) Current Concepts and Treatments of Schizophrenia. Molecules 23:8, pages 2087.
Crossref
Crossref
Sabine Mogwitz, Judith Buse, Nicole Wolff & Veit Roessner. (2018) Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents. ACS Chemical Neuroscience 9:4, pages 651-672.
Crossref
Crossref
Henk S Temmingh, Taryn Williams, Nandi Siegfried & Dan J Stein. (2018) Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Cochrane Database of Systematic Reviews 2018:2.
Crossref
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
241
267
.
Xiao-Wen Chen, Yu Liu, Xun-Qi Jin, Yuan-Yuan Sun, Shun-Lin Gu, Lei Fu & Jian-Qi Li. (2016)
Development and Kilogram-Scale Synthesis of a D
2
/5-HT
2A
Receptor Dual Antagonist (±)-SIPI 6360
. Organic Process Research & Development 20:9, pages 1662-1667.
Crossref
Crossref
Henk S Temmingh, Taryn Amos, Nandi Siegfried & Dan J Stein. (2014) Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Gregorio Paolo MilaniMario Giovanni Bianchetti, Marta Benedetta Maria MazzoniFabio Triulzi, Massimo Carlo MauriCarlo Agostoni & Emilio Filippo Fossali. (2014) Arterial Hypertension and Posterior Reversible Cerebral Edema Syndrome Induced by Risperidone. Pediatrics 133:3, pages e771-e774.
Crossref
Crossref
Yun Liu, Meng-qi Zhang, Jing-ying Jia, Yan-mei Liu, Gang-yi Liu, Shui-jun Li, Wei Wang, Li-ping Weng & Chen Yu. (2012) Bioequivalence and Pharmacokinetic Evaluation of Two Formulations of Risperidone 2 mg. Drugs in R&D 13:1, pages 29-36.
Crossref
Crossref
Sabine Mogwitz, Judith Buse, Stefan Ehrlich & Veit Roessner. 2013. Advances in the Neurochemistry and Neuropharmacology of Tourette Syndrome. Advances in the Neurochemistry and Neuropharmacology of Tourette Syndrome
281
349
.
W. Wolfgang Fleischhacker & Alex Hofer. 2012. Handbuch der Psychopharmakotherapie. Handbuch der Psychopharmakotherapie
937
960
.
Zuzana TobiasovaKlaas H. B. van der LingenLawrence ScahillJames F. LeckmanYan ZhangWookjin ChaeJames T. McCrackenChristopher J. McDougleBenedetto VitielloElaine TierneyMichael G. AmanL. Eugene ArnoldLiliya KatsovichPieter J. HoekstraFred VolkmarAlfred L. M. BothwellIvana Kawikova. (2011) Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal of Child and Adolescent Psychopharmacology 21:6, pages 555-564.
Crossref
Crossref
Marilyn A. DaviesYvette Conley & Bryan L. Roth. (2010)
Functional SNPs in Genes Encoding the 5-HT
2A
Receptor Modify the Affinity and Potency of Several Atypical Antipsychotic Drugs
. Biological Research For Nursing 13:1, pages 55-60.
Crossref
Crossref
S. Kasper & H.-J. Möller. 2011. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
731
766
.
RE Kast. (2010) Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines. British Journal of Pharmacology 161:3, pages 481-487.
Crossref
Crossref
Trisha A. Jenkins, Jennifer J. Elliott, Tara C. Ardis, Marie Cahir, Gavin P. Reynolds, Robert Bell & Stephen J. Cooper. (2010) Tryptophan depletion impairs object-recognition memory in the rat: Reversal by risperidone. Behavioural Brain Research 208:2, pages 479-483.
Crossref
Crossref
Shu-Feng Zhou. (2009) Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Clinical Pharmacokinetics 48:12, pages 761-804.
Crossref
Crossref
Chunbo Li, Jun Xia & Jijun Wang. (2009) Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Sandeep Chaudhary, Stevan Pecic, Onica LeGendre, Hérnan A. Navarro & Wayne W. Harding. (2009) (±)-Nantenine analogs as antagonists at human 5-HT2A receptors: C1 and flexible congeners. Bioorganic & Medicinal Chemistry Letters 19:9, pages 2530-2532.
Crossref
Crossref
Chunbo Li, Jun Xia & Jijun Wang. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Nitza Thomasson-Perret, Pierre-François Pénélaud, David Théron, Sylvie Gouttefangeas & Elisabeth Mocaër. (2008) Markers of D2 and D3 Receptor Activity in vivo: PET Scan and Prolactin. Therapies 63:3, pages 237-242.
Crossref
Crossref
VA Curtis, K. Katsafouros, H-J. Möller, R. Medori & E. Sacchetti. (2008) Long-acting risperidone improves negative symptoms in stable psychotic patients. Journal of Psychopharmacology 22:3, pages 254-261.
Crossref
Crossref
I. Hermecz & L. Vasvári-Debreczy. 2008. Comprehensive Heterocyclic Chemistry III. Comprehensive Heterocyclic Chemistry III
77
217
.
W. Wolfgang Fleischhacker, Martina Hummer & Alex Hofer. 2008. Handbuch der Psychopharmakotherapie. Handbuch der Psychopharmakotherapie
847
872
.
R Hashimoto, H Hashimoto, N Shintani, S Chiba, S Hattori, T Okada, M Nakajima, K Tanaka, N Kawagishi, K Nemoto, T Mori, T Ohnishi, H Noguchi, H Hori, T Suzuki, N Iwata, N Ozaki, T Nakabayashi, O Saitoh, A Kosuga, M Tatsumi, K Kamijima, D R Weinberger, H Kunugi & A Baba. (2007) Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Molecular Psychiatry 12:11, pages 1026-1032.
Crossref
Crossref
Catarina CorreiaAstrid M Vicente. (2007) Pharmacogenetics of risperidone response and induced side effects. Personalized Medicine 4:3, pages 271-293.
Crossref
Crossref
M. Pérez, I. Tůma, O. Pytela, E. Kadlecová, M. Zemanová & Z. Lenderová. (2020) El inhibidor de la acetilcolinesterasa donepecilo en el tratamiento del déficit cognitivo en la esquizofrenia. Subanálisis del grupo activo del estudio doble ciego extendido checo. European psychiatry (Ed. Española) 14:3, pages 140-142.
Crossref
Crossref
Hans-J??rgen M??ller. (2007) Long-Acting Injectable Risperidone for the Treatment of Schizophrenia. Drugs 67:11, pages 1541-1566.
Crossref
Crossref
Christos G Theleritis, George N Papadimitriou, Charalabos C Papageorgiou, Dimitris G Dikeos, Vasilis Masdrakis, Constantin Kostoulas, Constantin Psarros & Constantin R Soldatos. (2006) Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. BMC Psychiatry 6:1.
Crossref
Crossref
M. Pérez, I. Tůma, O. Pytela, E. Kadlecová, M. Zemanová & Z. Lenderová. (2020) Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study. European Psychiatry 21:8, pages 548-550.
Crossref
Crossref
Cornelis J. Van der Schyf, Werner J. Geldenhuys & Moussa B. H. Youdim. (2006) Multifunctional drugs with different CNS targets for neuropsychiatric disorders. Journal of Neurochemistry 99:4, pages 1033-1048.
Crossref
Crossref
W. W. Fleischhacker & M. Hummer. (2006) Pharmakotherapie der SchizophreniePharmacotherapy for schizophrenia. Der Nervenarzt 77:S03, pages S77-S98.
Crossref
Crossref
Hans-Jürgen Möller. (2006) Long-acting risperidone: Focus on safety. Clinical Therapeutics 28:5, pages 633-651.
Crossref
Crossref
Guy Faulkner & David Carless. (2006) Physical activity in the process of psychiatric rehabilitation: Theoretical and methodological issues.. Psychiatric Rehabilitation Journal 29:4, pages 258-266.
Crossref
Crossref
Frank-Gerald Pajonk. (2005) Clinical trial design in schizophrenia: implications for clinical decisions. Current Opinion in Psychiatry 18:6, pages 692-699.
Crossref
Crossref
Prakash S. Masand, Charles B. Nemeroff, John W. Newcomer, Jeffrey A. Lieberman, Alan F. Schatzberg, Peter J. Weiden, Clinton D. Kilts, Philip D. Harvey & David G. Daniel. (2014) From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone. CNS Spectrums 10:S17, pages 1-20.
Crossref
Crossref